{"groups":[{"description":"Patients receive doxorubicin IV over approximately 15-30 minutes on day 1, cisplatin IV over 60-90 minutes on day 1, paclitaxel IV over 3 hours on day 2, and filgrastim SC on days 3-12 or pegfilgrastim SC on day 3. Treatment repeats every 21 days for 7 courses in the absence of disease progression or unacceptable toxicity.","id":"FG000","title":"Doxorubicin, Cisplatin, Paclitaxel"},{"description":"Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30-60 minutes on day 1. Treatment repeats every 21 days for 7 courses in the absence of disease progression or unacceptable toxicity.","id":"FG001","title":"Paclitaxel, Carboplatin"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"44"},{"groupId":"FG001","numSubjects":"24"}],"type":"Ineligible"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"692"},{"groupId":"FG001","numSubjects":"689"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"647"},{"groupId":"FG001","numSubjects":"665"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"45"},{"groupId":"FG001","numSubjects":"24"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"recruitmentDetails":"GOG 0209 accrued 1381 patients from August 2003 to April 2009. 1312 of these patients were eligible."}